This company has been marked as potentially delisted and may not be actively trading. NASDAQ:INNT Innovate Biopharmaceuticals (INNT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisNews and Trends About Innovate Biopharmaceuticals Stock (NASDAQ:INNT) Get INNT alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.56▼$1.4252-Week Range N/AVolumeN/AAverage Volume525,982 shsMarket Capitalization$21 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina. Read More Receive INNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innovate Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INNT Stock News HeadlinesMinistry of Food and Drug Safety of Korea, Accelerates the Pace of Innovation for the Great Leap in BioAugust 26 at 6:41 PM | finance.yahoo.comAlabama-Based Simparo Inc. Earns Fourth U.S. Patent, Backed by Innovate Alabama InvestmentAugust 1, 2026 | finance.yahoo.comIt’s not about GreenlandThe petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then, China has cut its Treasury holdings by 45% from their peak, and BRICS nations offloaded $47 billion of American debt in a single month. The Trump administration has responded with a $12 billion critical minerals stockpile called Project Vault, equity stakes in miners like MP Materials and Lithium Americas, and a push to secure resources from Greenland to Ukraine. Porter Stansberry lays out the full story in a new documentary, including five companies positioned at the chokepoints of what he calls Trump's New Dollar.August 28 at 1:00 AM | Porter & Company (Ad)Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D ConsortiumJuly 27, 2026 | finance.yahoo.comWhat kind of company is Henlius? A global biopharmaceutical company driving innovation worldwideJuly 22, 2026 | msn.comDelveInsight Business Research, LLP: Global Biopharmaceutical Processing Equipment & Consumables Market is Anticipated to Cross the USD 110 Billion Mark by 2034 | DelveInsightJuly 7, 2026 | finanznachrichten.deProvectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant ...July 2, 2026 | finanznachrichten.deMajor breakthrough of Sanyou Biopharmaceuticals AI-STALMay 20, 2026 | finance.yahoo.comSee More Headlines INNT Stock Analysis - Frequently Asked Questions How were Innovate Biopharmaceuticals' earnings last quarter? Innovate Biopharmaceuticals Inc (NASDAQ:INNT) issued its quarterly earnings data on Monday, March, 18th. The company reported ($0.11) EPS for the quarter, hitting analysts' consensus estimates of ($0.11). What other stocks do shareholders of Innovate Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Innovate Biopharmaceuticals investors own include 9 Meters Biopharma (NMTR), NIO (NIO), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET), Iterum Therapeutics (ITRM), Meta Platforms (META) and Micron Technology (MU). Company Calendar Last Earnings3/18/2019Today8/28/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:INNT CIK1551986 Webwww.innovatebiopharma.com Phone919-275-1933FaxN/AEmployees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.05 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-234.42% Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / BookN/AMiscellaneous Outstanding Shares41,325,000Free FloatN/AMarket Cap$21 thousand OptionableNot Optionable Beta-0.39 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:INNT) was last updated on 8/28/2026 by MarketBeat.com Staff. From Our PartnersATTENTION: We just released a new “must-see” exposé on your retirementWeiss Ratings, the watchdog that has flagged major financial shifts for 55 years, is warning about a little-kn...Weiss Ratings | SponsoredThe "Misery Index" just hit a 3-year highThe Misery Index, inflation rate plus unemployment rate, just rose for a fourth straight month to a three year...American Alternative | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredWhy I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...Decentralized Masters | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovate Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovate Biopharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INNT Stock Alerts